Last reviewed · How we verify
Magnesium Hydroaspartate (magnesium aspartate)
Magnesium Hydroaspartate (generic name: magnesium aspartate) is a magnesium aspartate drug. It is currently in unknown development for Constipation, Hypokalemia, Hypokalemia Prevention.
Magnesium Hydroaspartate works by replenishing magnesium levels in the body, which helps to relax muscles and improve bowel function.
Magnesium Hydroaspartate, also known as magnesium aspartate, is a small molecule drug in the magnesium aspartate class. It is used to treat various gastrointestinal conditions, including constipation, indigestion, and hypomagnesemia. The commercial status of Magnesium Hydroaspartate is unknown, but it is likely available as a generic medication. Key safety considerations include potential gastrointestinal side effects and interactions with other medications. Further research is needed to fully understand its pharmacokinetics and pharmacodynamics.
At a glance
| Generic name | magnesium aspartate |
|---|---|
| Drug class | magnesium aspartate |
| Therapeutic area | Gastroenterology |
| Phase | unknown |
Mechanism of action
Think of it like a key that unlocks the muscles in your digestive tract. When you have enough magnesium, your muscles can relax and let food pass through more easily. This helps to prevent constipation and other gastrointestinal problems.
Approved indications
- Constipation
- Hypokalemia
- Hypokalemia Prevention
- Hypomagnesemia
- Incomplete passage of stool
- Indigestion
Common side effects
- Fractional exhaled nitric oxide increased
- Infective exacerbation of chronic obstructive airways disease
- Listless
- Myoglobin blood increased
- Reduced facial expression
- Plantar fasciitis
- Sensation of foreign body
- Nerve degeneration
- Hypomagnesaemia
- Reflexes abnormal
- Brain natriuretic peptide increased
- Apathy
Key clinical trials
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2,PHASE3)
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Neurobiology of Suicide (PHASE2)
- Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (PHASE2)
- Pharmacokinetics of Zelquistinel in Fasted or Fed State (PHASE1)
- A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (PHASE2)
- The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules (PHASE4)
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnesium Hydroaspartate CI brief — competitive landscape report
- Magnesium Hydroaspartate updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Magnesium Hydroaspartate
What is Magnesium Hydroaspartate?
How does Magnesium Hydroaspartate work?
What is Magnesium Hydroaspartate used for?
What is the generic name of Magnesium Hydroaspartate?
What drug class is Magnesium Hydroaspartate in?
What development phase is Magnesium Hydroaspartate in?
What are the side effects of Magnesium Hydroaspartate?
Related
- Drug class: All magnesium aspartate drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Constipation
- Indication: Drugs for Hypokalemia
- Indication: Drugs for Hypokalemia Prevention
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing